DBVT - DBVテクノロジ―ズ （DBV Technologies S.A.） DBVテクノロジ―ズDBVTのチャート
DBVTの企業情報
| symbol | DBVT |
|---|---|
| 会社名 | DBV Technologies Boulogne-Billancourt （DBVテクノロジ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- DBVテクノロジ―ズはフランスの臨床段階のバイオ医薬品メ―カ―。「Viaskin」と呼ばれる免疫療法分野の新技術プラットフォ―ムを開発。「Viaskin」は患者に自己管理、非侵襲性の免疫療法を提供する貼り薬(パッチ)。重度の食物アレルギ―の幼児や子どもを含む患者の治療にもこの技術が応用される。 |
| 本社所在地 | 177-181 avenue Pierre-Brossolette Montrouge 92120 FRA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 37316 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 244人 |
| url | www.dbv-technologies.com |
| nasdaq_url | https://www.nasdaq.com/symbol/dbvt |
| adr_tso | 26750330 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 18.55 |
| 時価総額（marketcap） | 496218621.5 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
DBVTのテクニカル分析
DBVTのニュース
DBV Technologies GAAP EPS of -$0.22, revenue of $2.2M 2023/05/04 21:40:03 Seeking Alpha
DBV Technologies press release (NASDAQ:DBVT): Q1 GAAP EPS of -$0.22.Revenue of $2.2M (-12.0% Y/Y).
DBV Technologies S.A.: DBV Technologies Reports First Quarter 2023 Financial Results 2023/05/04 20:34:00 Finanz Nachrichten
Montrouge, France, May 4, 2023 DBV Technologies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million. DBV Technologies (Euronext: DBV - I…
VUZI, CZOO and DBVT are among pre market gainers 2023/04/28 12:29:31 Seeking Alpha
TOP Financial Group (TOP) +272% brokerage TOP Financial sees stock soar 195%.AGBA Group Holding (AGBA) +75%. Golden Sun Education Group (GSUN) +63%
DBV Technologies Outlines Regulatory Path For Viaskin Peanut Allergy Patch For Kids Below 3 Years 2023/04/20 16:26:38 Benzinga
DBV Technologies (NASDAQ: DBVT ) received written responses from the FDA on the regulatory path for the investigational Viaskin Peanut 250 μg patch (DBV712) in toddlers ages 1 – 3 years old with a confirmed peanut allergy. In the written responses received, the agency confirmed that the Company''s Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint. The FDA did not request an additional efficacy … Full story available on Benzinga.com
DBV Technologies S.A.: DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting 2023/04/12 20:34:00 Finanz Nachrichten
Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext…
VUZI, CZOO and DBVT are among pre market gainers 2023/04/28 12:29:31 Seeking Alpha
TOP Financial Group (TOP) +272% brokerage TOP Financial sees stock soar 195%.AGBA Group Holding (AGBA) +75%. Golden Sun Education Group (GSUN) +63%
DBV Technologies Outlines Regulatory Path For Viaskin Peanut Allergy Patch For Kids Below 3 Years 2023/04/20 16:26:38 Benzinga
DBV Technologies (NASDAQ: DBVT ) received written responses from the FDA on the regulatory path for the investigational Viaskin Peanut 250 μg patch (DBV712) in toddlers ages 1 – 3 years old with a confirmed peanut allergy. In the written responses received, the agency confirmed that the Company''s Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint. The FDA did not request an additional efficacy … Full story available on Benzinga.com
DBV Technologies S.A.: DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting 2023/04/12 20:34:00 Finanz Nachrichten
Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext…
DBV Technologies Announces Results of its 2023 Ordinary and 2023/04/12 20:30:00 businessfortnight.com
Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting Shareholders Approved All Proposed Resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, […] The post DBV Technologies Announces Results of its 2023 Ordinary and appeared first on Businessfortnight .
DBV Technologies files for $250M mixed shelf offering 2023/04/06 21:34:13 Seeking Alpha
DBV Technologies (DBVT) on Thursday filed for a mixed shelf offering of up to $250M. Read more here.
Why DBV Technologies Stock Is Soaring Today 2022/12/23 17:01:17 The Motley Fool
The company can now move forward with a late-stage study of its lead pipeline candidate.
Thinking about buying stock in Core Scientific, DBV Technologies, Gaotu Techedu, New Oriental Education, or Ardelyx? 2022/12/23 15:41:00 Kwhen Finance
CHRS, MESA and REKR are among pre market gainers 2022/12/23 13:12:38 Seeking Alpha
AMC Entertainment Holdings (APE) +53%. Immuron (IMRN) +43% as FDA clears clinical trial for infectious diarrhea candidate.DBV Technologies (DBVT) +31% as FDA lifts partial hold on…
DBV Tech Rises after FDA Lifts Hold on Phase 3 Trial 2022/12/23 12:30:12 TipRanks
Shares of biopharmaceutical company DBV Technologies (NASDAQ:DBVT) are rising today after the U.S. Food and Drug Administration lifted the partial …
DBV stock soars 30% as FDA lifts partial hold on phase 3 trial of peanut allergy patch 2022/12/23 11:05:11 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) lifted a partial clinical hold on DBV Technologies (DBVT) (DBVTF) phase 3 trial which will evaluate the modified Viaskin Peanut 250 μg…